Working... Menu

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03804541
Recruitment Status : Recruiting
First Posted : January 15, 2019
Last Update Posted : January 15, 2019
Information provided by (Responsible Party):
Betta Pharmaceuticals Co., Ltd.

Brief Summary:
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects. The study will be conducted into two steps:Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the completion date of plasma, urine and feces sampling on the 3rd day post-dose and onwards. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 4-6 subjects will be adjusted according to the pilot study.

Condition or disease Intervention/treatment Phase
ALK-POSITIVE NSCLC Drug: Ensartinib Phase 1

Detailed Description:
Subjects who had signed informed consent and meet inclusion criteria and no exclusion criteria are admitted to Phase I Clinical Unit two days prior to dosing (D-2). On the morning of Day 1 before dosing, subjects will be transferred to nuclear medical ward. And after an overnight fast of at least 10 h, subjects will receive a single oral dose of 200 mg (100 μCi) of [14C]Ensartinib as an oral suspension. Then, after two days of the dosing, subjects will be transferred back to Phase I Clinical Unit ward and confined to this unit until blood or excreta sampling and safety monitoring at the designated time points or intervals are complete

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]Ensartinib (X-396) After a Single Oral 200mg (100µCi) Dose in Healthy Chinese Male Subjects
Actual Study Start Date : December 28, 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : October 2019

Arm Intervention/treatment
Experimental: [14C]Ensartinib
To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
Drug: Ensartinib
A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Other Name: X-396

Primary Outcome Measures :
  1. Radioactivity concentration of each plasma sample [ Time Frame: Day1-Day15 ]
    Use liquid scintillation counter to evaluate Radioactivity concentration of each plasma(DPM/ml) sample

  2. Radioactivity concentration of each urine samples [ Time Frame: Day1-Day15 ]
    Use liquid scintillation counter to evaluate Radioactivity concentration of each urine(DPM/ml) sample

  3. Radioactivity concentration of each feces sample [ Time Frame: Day1-Day15 ]
    Use liquid scintillation counter to evaluate Radioactivity concentration of each feces(DPM/g) sample

  4. Total recovery of radioactivity in urine and feces [ Time Frame: Day1-Day15 ]
    Calculate the total radioactivity in urine and feces based on the radioactivity concentration of each sample.

Secondary Outcome Measures :
  1. Plasma drug concentrations [ Time Frame: Day1-Day15 ]
    To determine the plasma concentrations of Ensartinib with validated LC-MS/MS method for obtaining its pharmacokinetics parameters;

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: Day1-Day15 ]
    According to CTCAE v4.03, the number and frequency of adverse events after a single dose of test drug were assessed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

A subject will be eligible for study participation if he meets the following criteria:

  1. healthy male volunteers between the ages of 18 to 50 years old, inclusive;
  2. Body weight >=50 kg, Body mass index (body weight(kg)/hight2(m2)) between 19 and 26 kg/m2 (inclusive);
  3. Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant;
  4. Male subjects of reproductive potential with partners will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 1 year after discontinuing treatment with the investigational product. Highly effective methods of birth control include using condom, contraceptive sponge, contraceptive gel, contraceptive film, intrauterine device, oral or injectable contraceptive pill, hypodermic implants or others;
  5. Must understand, and voluntarily sign the informed consent, comply with the requirements of the study

Exclusion Criteria:

A subject will not be eligible for study participation if he meets any of the exclusion criteria:

  1. History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;
  2. Positive test for HBsAg, HBeAg, anti-HCV, anti-HIV or syphilis antibody;
  3. History of clinically significant disease or infection within 1 month before entering the study;
  4. Abnormality in blood pressure, including hypertensive BP (SBP>=140 mmHg, or DBP >=90 mmHg), or hypotensive BP(SBP<90 mmHg, or DBP <=55 mmHg), Pulse rate<55 bpm or >100 bpm;
  5. Long-QT syndrome or family history of it, or QTcB interval > 450 ms; intraventricular blocks or left/right bundle branch block or QRS>120ms; frequent ventricular ectopic beats (any 10s ECG ventricular premature beat >= 1 in screening period); or abnormal resting heart rate (> 100 bpm)
  6. The following abnormal clinical laboratory values

    1. HGB < LLN, and is judged as clinically significant by the investigator;
    2. Abnormal ALP, ALB,TP,CRE,ALT,AST,BIL,BUN, GLU value, and is judged as clinically significant by the investigator;
  7. Received any drug within 14 days before taking the investigational drug, including any prescription drug, OTC drug or herbal drug, except for vitamins and paracetamol;
  8. History of or current swallowing disorder, active gastrointestinal diseases, or other diseases that significantly affect absorption, distribution, metabolism and excretion of drugs;
  9. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease;
  10. Hemorrhoids or perianal disease with regular/perianal bleeding;
  11. Allergies, have allergies to two or more drugs or foods; or have known allergies to the components of the drug (microcrystalline cellulose, stearic acid, hydroxypropyl methylcellulose);
  12. Have donated 500ml or more of blood or plasma 2 months prior to the study drug administration, or more than 50ml within 2 weeks prior to administration;
  13. Vaccination was administered within 6 months prior to screening or during screening;
  14. History of drug or alcohol abuse;
  15. Smoking (> 10 cigarette / day), drinking (> 15 g, pure alcohol / day, equivalent to 450 ml beer, 150 ml wine or 50 ml low-alcohol liquor), or abusing drugs(MOP, METmAMP, MTD, THC, AMP positive) within last 3 months;
  16. Subject with mentally ill and could not understand the property, scope and possible consequences of the study;
  17. subject in prison or whose freedom is restricted by administrative or legal issues;
  18. Failure to comply with clinical study protocols, such as non-cooperation, follow-up visit and completion of entire study;
  19. Investigator, pharmacist, CRC or research associate;
  20. Investigators think that subjects are not suitable to participate in the study;
  21. Subjects who have participated in radiolabeled clinical study prior to drug administration;
  22. Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03804541

Layout table for location contacts
Contact: Feng Shao +8613851691161
Contact: Sufeng Zhou +8615952052032

Layout table for location information
China, Jiangsu Provence
Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine Recruiting
Nanjing, Jiangsu Provence, China, 210005
Contact: Feng Shao,Associate Professor, PhD    +8613851691161   
Sponsors and Collaborators
Betta Pharmaceuticals Co., Ltd.
Layout table for investigator information
Principal Investigator: Feng Shao Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Betta Pharmaceuticals Co., Ltd. Identifier: NCT03804541     History of Changes
Other Study ID Numbers: BTP-44316
First Posted: January 15, 2019    Key Record Dates
Last Update Posted: January 15, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action